Recombinant Bovine Growth Hormone vs Azodicarbonamide: which is worse?

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

What is Azodicarbonamide?

Azodicarbonamide (ADA) is a synthetic chemical used in the food industry as a flour bleaching agent and dough conditioner, and industrially as a blowing agent in foam rubber and plastic production. Its chemical formula is C2H4N4O2. When it reacts with water or heat, it breaks down into biurea (primary product) and semicarbazide (SEM).

Documented risks

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.

Azodicarbonamide: ADA's primary food safety concern is its breakdown to semicarbazide (SEM) during baking. In a 2002 study, SEM was found to increase the incidence of vascular tumors in female mice at high doses. This single animal finding was sufficient under the EU's precautionary principle to ban ADA in food use in 2005. The FDA conducted a comprehensive SEM exposure assessment in 2016, concluding that US population exposure to SEM from ADA-treated bread is many orders of magnitude below doses showing tumor effects in rodents and does not warrant regulatory change. This reflects the FDA's risk-based approach. Urethane (ethyl carbamate) is another potentially harmful breakdown product of ADA. Urethane is classified as an IARC Group 2A probable human carcinogen. Small amounts of urethane can form from SEM in fermented or alcohol-containing environments. The 2014 'yoga mat chemical' controversy highlighted ADA's dual use: it is the same chemical used as a blowing agent in foam rubber and plastic manufacturing — including yoga mats. Consumer advocacy blogger Vani Hari's 'Food Babe' campaign led over 50,000 people to petition Subway, which voluntarily removed ADA from its bread in 2014. The dual industrial-food use raised public concern even though ADA's behavior in each context is chemically different. From occupational health: workers exposed to ADA powder in bakery or plastic manufacturing settings can develop occupational asthma. WHO recognizes ADA as a respiratory sensitizer in occupational settings, though dietary exposure through bread is fundamentally different from inhalation exposure.